<div id="readability-page-1"><div> (RTTNews) - CAMP4 Therapeutics Corporation (CAMP), a clinical-stage biopharmaceutical company, on Thursday released its first-quarter financial results and provided various business highlights. The company specializes in developing RNA-targeted therapies to upregulate gene expression to effectively treat genetic diseases. Q1 2026: The company reported a net loss of $18.33 million, or $0.32 per share, in Q1 2026, while in the same period of 2025, the net loss was $12.43 million, or $0.62 per share. Research and development expenses (R&amp;D) were $10.16 million, relatively stable compared to $10.15 million in the previous year. Cash, cash equivalents, and marketable securities on March 31, 2026, amounted to $99.21 million. Business Updates: CAMP4 submitted a regulatory filing in Australia to enable a Phase 1/2 clinical trial for CMP-002 in the second half of 2026. CMP-002, a first-in-class treatment for SYNGAP1-related disorders, was also granted an orphan drug designation by the European Medicines Agency (EMA) and filed to receive an orphan drug designation from the FDA. The company also began a collaboration with CURE SYNGAP for the ProMMis study to determine the natural history of SYNGAP1-related disorders and to develop effective therapies. A preprint of a pioneering study was submitted, outlining regRNA capture sequencing to create the largest catalog of regRNAs. CAMP is currently trading at $4.27, down 1.50%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. </div></div>

CAMP

SBIO

LABU

CAMP4 Therapeutics Corporation reported a net loss of $18.33 million in Q1 2026, compared to a loss of $12.43 million in Q1 2025. R&D expenses remained stable at $10.16 million. The company has $99.21 million in cash and equivalents. CAMP4 is advancing CMP-002 for SYNGAP1-related disorders, with a Phase 1/2 trial expected in late 2026 and orphan drug designations from the EMA and FDA. The stock is currently trading at $4.27, down 1.50%.

nasdaq

CAMP4 Therapeutics

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Nasdaq

CAMP4 Reports Net Loss Of $18 Mln In Q1; Advances CMP-002 For SYNGAP1-related Disorders